Review Finds Alzheimer's Drugs Offer Limited Benefits, Sparking Debate
A major review by the Cochrane organization has found that drugs targeting amyloid plaques in Alzheimer's patients do not provide meaningful benefits. These drugs, including lecanemab and donanemab, were initially seen as breakthroughs in slowing Alzheimer's progression. However, the review, which analyzed data from 17 clinical trials involving over 20,000 participants, concluded that while these drugs remove amyloids, they do not translate into significant clinical improvements for patients. The findings have sparked debate among experts, with some criticizing the review's methodology and others calling for a shift in research focus. 
